@misc{10481/80721,
year = {2023},
month = {1},
url = {https://hdl.handle.net/10481/80721},
abstract = {Severe Uncontrolled Asthma (SUA) counts for more than 25% of cases of severe asthma.
The main factors that impair the quality of life of these patients are high doses of oral corticosteroids,
the presence of exacerbations, and reduced lung function. The objective of this study was to evaluate,
in real life, the clinical improvement of patients with SUA treated with anti-interleukin 5 (IL5)
therapies: mepolizumab and benralizumab, together with the search for biomarkers associated with
the response. We conducted a retrospective observational cohort study that included patients with
severe uncontrolled eosinophilic asthma in a tertiary hospital receiving biological therapies. Three
types of response were evaluated: improvement in lung function, reduction in exacerbations, and
decrease in the use of oral corticosteroids. After 12 months of treatment, significant reductions were
found in the number of exacerbations, the use of oral corticosteroids, and blood eosinophil levels for
both biological therapies (p < 0.001). Lung function improved, achieving a significant improvement
in %FEV1 (p < 0.001), as well as asthma control, with a significant increase in asthma control test
(ACT) scores in both therapies. The markers associated with the corticosteroid-saving effect were
the low doses of oral corticosteroids and absence of exacerbations for mepolizumab, and higher
blood eosinophilia, absence of chronic obstructive pulmonary disease (COPD), and reduction in oral
corticosteroid cycles for benralizumab. The greatest improvement in lung function in both therapies
was linked to lower previous FEV1 levels and absence of other respiratory diseases. The reduction in
exacerbations was associated with absence of exacerbations the previous year for mepolizumab and
never smokers for benralizumab. The results of this real-life study confirm the clinical benefit obtained
after the introduction of an anti-IL5 biological therapy and the possible predictive biomarkers of
response to treatment.},
organization = {Instituto de Salud Carlos III (PT13/0010/0039) Biobank of the Hospital Universitario Virgen de las Nieves},
publisher = {MDPI},
keywords = {Severe uncontrolled asthma},
keywords = {Mepolizumab},
keywords = {Benralizumab},
keywords = {Effectiveness},
keywords = {Biomarkers},
title = {Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study},
doi = {10.3390/ijms24032011},
author = {Rojo Tolosa, Susana and González Gutiérrez, María Victoria and Jiménez Gálvez, Gonzalo and Sánchez Martínez, José Antonio and Pineda Lancheros, Laura Elena and Gálvez Navas, José María and Jiménez Morales, Alberto and Pérez Ramírez, Cristina and Morales García, Concepción},
}